LADR-7 / LadRx - LARVOL DELTA

LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License (Businesswire) - "LadRx Corporation...is pleased to announce that the Company and NantCell, Inc...together with NantCell’s parent company ImmunityBio, Inc. ('ImmunityBio'), have agreed to a mutual termination of the license of aldoxorubicin entered into in 2017...With the termination of the license agreement between LadRx and NantCell, LadRx regains control of aldoxorubicin...XOMA consented to the mutual termination of the LadRx-NantCell agreement in order to facilitate the return of the program to LadRx...The agreement between LadRx and XOMA regarding future royalties and milestones associated with arimoclomol is not affected by the termination of the aldoxorubicin license between LadRx and NantCell....'we continue to march LADR-7 towards the clinic and remain on track for filing an IND application for LADR-7 in the third or fourth quarter of 2024.'"

IND • Licensing / partnership • CNS Disorders • Oncology • Sarcoma • Soft Tissue Sarcoma • Solid Tumor